1. Liu et al. Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy. Cancers. 2020, 12(4), 1025.

2. Chen et al. Functional comparison of interferon‐α subtypes reveals potent hepatitis B virus suppression by a concerted action of interferon‐α and interferon‐γ signaling. Hepatology. 2021 Feb;73(2):486-502.

3. Sundar et al. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. Gut. 2022 Jul 1;71(7):1277-88.

4. Jhajharia et al. Defining the specificity and function of a human neutralizing antibody for Hepatitis B virus. npj Vaccines. 2022 Oct 21;7(1):121.

5. Liu et al. Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model. Science Advances. 2022 Nov 23;8(47):eadd1187.

6. Zhao et al. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut. 2018 Oct 1;67(10):1845-54.

7. Zhao et al. Analysis and validation of human targets and treatments using a hepatocellular carcinoma–immune humanized mouse model. Hepatology. 2021 Sep;74(3):1395-410.